1

2

3

4

5

“ ”

1 2021

2 35

A

3

30% 2021

400,108,752

120,032,625

4

20

A 80%

20 = 20

/ 20

5 100,000.00

1	š	Ĭ	

6

A A

7

8

[2012]37 3 —

“

”

9

10 A

[2014]17

[2013]110

[2015]31

“ ”

11

12 “ ”

.....2

.....3

.....7

.....9

A 10

.....10

.....10

.....14

.....14

.....17

.....17

.....18

.....19

.....19

.....19

.....26

.....27

.....28

.....28

.....29

.....29

.....29

		2021 A

A

	Hainan Huluwa Pharmaceutical Group Co., Ltd.
	605199.SH
	2005 6 22
	2020 7 10
	400,108,752
	8
	8
	0898-6868 9766
	0898-6863 1245
	www.huluwayaoye.com
	hnhlwyyjtgf@163.com
	“ ” 168 6

1

2

3

4

3

2019

1

2

3

4

5

6

2014-2018 6.9%

2018 14,975.4

8.3% 2023

22,367.7

2014-2018

5,806.5 6,309.4

2.1% 6.0%

2023 8,443.4

1

95% 90%

85% 80%

2 3

2

3

35

A

1.00

35

35

30% 2021

400,108,752

120,032,625

12

100,000.00

1		58,870.43	44,320.00
2		32,866.62	25,680.00
3		30,000.00	30,000.00
		121,737.05	100,000.00

35

60% 25.06%

0.42% 0.03% 1,095.60

2.74% 40% 16.70%

67.08% 5.51%

50.04%

12,003.2625

38.49%

2021 2 9 2021

100,000.00

100,000.00

1		58,870.43	44,320.00
2		32,866.62	25,680.00
3		30,000.00	30,000.00
		121,737.05	100,000.00

1

1

58,870.43

44,320.00

2

1# 2# 3# 4#

（2 ）

2

1

90%

2016

3500 60 1.7%

6000 10 2017

17.1

2650 1.55% 400

2019

2

95% 90%

85%

80% 2 3

3

1

“ ”

5 0-4

0-4

5-14

2007 9,797.73 2019 27,766.9

9.07%

2019

5% 16.78%

2018

750

2

1

“ ”

ŧ ŏ

2

3

1

GMP FDA

ICH Q10 ISO9001

2

2,000 10,000

20 27

OTC

4

5

2020-45011227-03-033159

27,854.07

6

19.79% 6.46

1

30,000.00

2

1

2

“

” “ ” “

”

“ ” “

”

2015 904 2015 6 1

2017 2 9

“ ”

2016 3

3

3

“ ”

2015

“ ”

“ ” “ ” “ ”

OTC

“ ”

“ ”

“ ” “

” “ ”

1

80%

2

40%

3

20%

10%

2

2/3

2020 7 10

2018 6 24 2017 2017 12 31
10 6.25
70,000,000

2019 11 14 2019 2019
6 30 10
2.25 81,001,969.20

2019	8,10020	12,032.93	67.32%
2018	-	10,053.88	0.00%
2017	7,000.00	2,212.79	316.34%
			15,100.20
			8,099.87
			186.43%

3 ——

2021-2023 “ ” “

”

2021-2023

1

2

10%

3

4

1

80%

2

40%

3

20%

2

2/3

2021

2021 2 9